-
Posted by
Two Blokes Tue at 10:30 AM -
Filed in
Stock
-
3 views
GeneDx delivered strong Q1 2025 results, beating revenue and EPS estimates, and raised full-year guidance despite a minor sequential test volume dip. The volume decline is attributable to seasonality, adverse weather, and one fewer business day, not a structural slowdown; fundamentals remain robust. Strong pricing power and rising reimbursement rates drive revenue growth, setting a solid foundation for future acceleration as volumes rebound.
